跳至主要内容
临床试验/NCT06102590
NCT06102590
招募中
不适用

Oxygen Extraction-guided Transfusion Strategy in Critically Ill Patients. A Randomized Controlled Trial.

Università degli Studi di Ferrara7 个研究点 分布在 2 个国家目标入组 324 人2023年11月4日

概览

阶段
不适用
干预措施
Individualized red blood cell transfusion strategy
疾病 / 适应症
Blood Transfusion
发起方
Università degli Studi di Ferrara
入组人数
324
试验地点
7
主要终点
Acute Kidney Injury (AKI)
状态
招募中
最后更新
昨天

概览

简要总结

In critically ill patients, optimized strategies for red blood cells transfusion (RBCT) are still controversial. Most recent guidelines suggest that clinical practice in ICU setting should follow a restrictive approach to RBCT (i.e., hemoglonim level < 7.0 g/dL).In our previous study, oxygen extraction ratio (O2ER) has shown good performance as a marker to identify the correct timing for RBCT, potentially affecting 90-day mortality in non-bleeding, critically ill patients [11]. Moreover, our data suggested that an individualized strategy for RBCT may reduce the incidence of acute kidney injury (AKI), which is possibly related to a better delivery of oxygen and organ perfusion.

注册库
clinicaltrials.gov
开始日期
2023年11月4日
结束日期
2027年1月1日
最后更新
昨天
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

发起方
Università degli Studi di Ferrara
责任方
Principal Investigator
主要研究者

Alberto Fogagnolo

Dr

Università degli Studi di Ferrara

入排标准

入选标准

  • Hb levels ≤ 9.0 g/dL (as confirmed through a blood test and/or through blood gas analysis)
  • Presence of an arterial line and a central venous line (either jugular or subclavian), with confirmed correct position of the catheter tip at the atrio-caval junction (allowing correct estimation of central venous saturation, ScvO2).

排除标准

  • Age \< 18 years;
  • Pregnancy
  • Clinical evidence of acute bleeding
  • Diagnosis of haematological malignancy
  • Diagnosis of sickle cell disease, or other diseases exposing the patient to chronic RCBTs
  • Acquired or congenital disorders of coagulation
  • Patients with ongoing AKI of stage 1 or worse and/or known chronic kidney disease (CKD) of stage G3a or worse, defined as glomerular filtration rate below 60 for a minimum of 3 months

研究组 & 干预措施

Individualized RBCT

Requires daily assessment of hemoglobin (Hb) levels. Prescription of RCBT is restricted to patients who present Hb ≤ 9.0 g/dL and O2ER ≥ 30%. If O2ER \< 30%, transfusion will take place only when Hb falls below 7.0 g/dL. Further O2ER measurements during the day in this group are allowed, and the clinician should not be blinded of the results. To tolerate Hb levels below 7.0 g/dL with O2ER \< 30% remains a clinical decision, documented in the CRF. Transfusion with Hb below 6.0 g/dL is mandatory

干预措施: Individualized red blood cell transfusion strategy

Control group

Requires daily assessment of hemoglobin levels. Prescription of RCBT is restricted to patients who present Hb ≤ 7.0 g/dL, despite of O2ER values. Indeed, O2ER calculation takes place at least once daily in this group but does not interfere with clinical decision to prescribe RBCT. A liberal transfusion threshold (i.e. 9.0 g/dL) is still possible in critically ill adults with acute coronary syndromes, as indicated by the European current guidelines

干预措施: European guidelines red blood cell transfusion strategy

结局指标

主要结局

Acute Kidney Injury (AKI)

时间窗: 7-day after study inclusion

Primary outcome will be the incidence of AKI, according to KDIGO latest definitions

次要结局

  • days on vasopressors(28 days)
  • In-hospital mortality(through study completion, an average of 180 days)
  • variations in myocardial-specific troponin(24 hours after study inclusion)
  • proportion of patients undergoing RBCT, despite adequate/low O2ER(28 days)
  • SOFA score variations(5 days)
  • Major Adverse Kidney Events by 90 days (MAKE90)(90 days)
  • ICU mortality(through study completion, an average of 180 days)
  • 90-day mortality(90-day after study inclusion)

研究点 (7)

Loading locations...

相似试验